Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising cocktail of drugs targets rare blood cancer

NCT ID NCT07574528

Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation in 47 people with newly diagnosed stage I/II extranodal NK/T-cell lymphoma, a rare blood cancer. The goal is to see how many patients achieve complete remission after treatment. It is an early-phase trial without a placebo group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sintilimab, pegaspargase, selinexor, and radiotherapy
What this could lead to
If successful, this combination could become a new first-line treatment option for early-stage NK/T-cell lymphoma, potentially improving response rates and reducing relapse.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 47 participants and no comparison group, so results may not be definitive. The drug combination may cause significant side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 47 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * No prior systemic treatment for lymphoma, except short-term corticosteroids for symptom control. * Life expectancy of more than 3 months. * Eastern Cooperative Oncology Group performance status of 0 to 2. * Histologically confirmed extranodal natural killer/T-cell lymphoma. * Primary lesion located in the nasal cavity or upper aerodigestive tract. * Stage I to II disease. * At least one measurable or evaluable lesion according to Lugano 2014 criteria. * Adequate organ and bone marrow function. Exclusion Criteria: * Aggressive NK-cell leukemia. * Significant dysfunction of major organs. * Known hypersensitivity to any study drug or its components, or contraindication to any study treatment. * Pregnant or breastfeeding women, or participants of childbearing potential unwilling to use effective contraception. * Known history of human immunodeficiency virus infection or acquired immunodeficiency syndrome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NKTCL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NKTCL

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sun Yat-sen University Cancer Center

    Guangzhou, 广东省 - Guangdong Sheng, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.